Major Adverse Cardiovascular Events in Patients with Melanoma Receiving Immune Checkpoint Inhibitors [0.03%]
免疫检查点抑制剂治疗黑色素瘤患者的心血管不良事件风险
Juan I Ruiz,Bo Zhao,Nicolas Palaskas et al.
Juan I Ruiz et al.
Introduction: Immune checkpoint inhibitors (ICIs) might increase the risk of major adverse cardiovascular events (MACEs). This study aimed to evaluate the risk of MACE in patients with melanoma after ICI initiation. ...
B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review [0.03%]
肿瘤临床试验中的B7同系物H4(B7-H4)靶向剂：综述
Meave Phipps,Gerald S Falchook
Meave Phipps
B7 homolog 4 (B7-H4) is a transmembrane protein found on immune cells and is frequently overexpressed in various solid tumors, making it a promising target for cancer therapy. B7-H4-directed agents, particularly antibody-drug conjugates (AD...
Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial [0.03%]
派姆单抗治疗晚期罕见肿瘤患者 II 期篮式试验的初步结果
Mirella Nardo,Camila Braganca Xavier,Bettzy Stephen et al.
Mirella Nardo et al.
Introduction: Rare solid tumors account for one-quarter of cancers among adults in the United States, but few resources have been devoted to their treatment. We evaluated the efficacy of pembrolizumab, a programmed cell d...
Robin Schwartz,Keerti Vajrala,Gerald S Falchook
Robin Schwartz
4-1BB is a transmembrane glycoprotein found on T lymphocytes, and signaling through 4-1BB activates and differentiates CD3+ and CD8+ T cells. The ability of 4-1BB to stimulate cytotoxic T-cell responses makes it a promising target for thera...
Advancing Understanding and Therapeutic Strategies for NUT Sarcomas: Comprehensive Review of the Literature and Two Cases [0.03%]
NUT肉瘤的理解与治疗策略进展：文献综合回顾及两例病例分析
Carlos Torrado,Elise Nassif Haddad,Neeta Somaiah et al.
Carlos Torrado et al.
Soft tissue sarcomas (STSs) are a group of rare cancers, among which nuclear protein in testis (NUT) sarcomas represent an ultra-rare subset driven by NUTM1 gene fusions. This article presents two unique cases of NUT sarcomas and conducts a...
Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non-Small Cell Lung Cancer: A Case Report [0.03%]
非小细胞肺癌中c-met抗体药物偶联物引起无症状肺炎使用新型激素治疗一例报告
Daniel A Fox,Christine Tran,Vincent Blot et al.
Daniel A Fox et al.
Antibody-drug conjugates (ADCs) are a potent class of antineoplastic drugs that deliver cytotoxic agents via targeting with monoclonal antibodies; however, ADCs are associated with high rates of lung toxicities, limiting the therapeutic pot...
Incidence and Factors Associated with Graft-Versus-Host Disease in the First Year After Allogeneic Peripheral Blood Stem Cell Transplantation [0.03%]
异基因外周血干细胞移植后一年内移植物抗宿主病的发生率及影响因素
Ulrike Heider,Julio Solano-Vega,Y Gisella Sandoval-Vargas et al.
Ulrike Heider et al.
Introduction: The use of allogeneic peripheral blood stem cell transplantation (allo-SCT) has increased in Latin America in recent years. In the absence of an matched-related donor (MRD), haploidentical transplantation ha...
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial [0.03%]
莱福特利莫德联合伊匹木单抗治疗晚期实体瘤患者：一项I期试验
Mirella Nardo,Mohamed A Gouda,Matthew J Reilley et al.
Mirella Nardo et al.
Introduction: TLR9 agonists are immunomodulators that have been of interest for combined use with cancer immunotherapy. TLR9 agonists, such as lefitolimod (MGN1703), significantly increased Th1 response in preclinical mod...
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study [0.03%]
特瑞普利单抗治疗胆管癌患者的安全性和疗效：一项开放标签I期研究
Aung Naing,Amit Mahipal,Milind Javle et al.
Aung Naing et al.
Introduction: This was the first phase 1 study conducted in the United States. It consisted of dose-escalation (part A) and multiple indication-specific cohort expansion (part B), investigating the safety and preliminary ...
Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial [0.03%]
塞利尼索(KPT-330)联合免疫检查点抑制剂治疗脉络膜黑色素瘤：一项II期临床试验
Mohamed A Gouda,Abdulrazzak Zarifa,Yali Yang et al.
Mohamed A Gouda et al.
Introduction: Uveal melanoma remains a disease with aggressive behavior and poor prognosis despite advances in clinical management. Because monotherapy with immune checkpoint inhibitors has led to limited improvement in r...